Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
نویسندگان
چکیده
Riociguat (Adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
منابع مشابه
Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
Although pulmonary endarterectomy remains the treatment of choice for patients with chronic thromboembolic pulmonary hypertension (CTEPH), not all patients will benefit from or receive this highly specialised surgery. Patients whose CTEPH is deemed inoperable by an experienced centre and patients with persistent pulmonary hypertension after surgery are candidates for trial of pulmonary arterial...
متن کاملDrug Therapy in Patients with Chronic Thromboembolic Pulmonary Hypertension
Background: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) results from the obstruction of predominantly major pulmonary vessels by organized blood clots and is one of the causes of pulmonary hypertension. The disease is still underdiagnosed and the true prevalence is not clear. The objective of this study was to determine the clinical characteristics and current management of patients w...
متن کاملEarly Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center
INTRODUCTION Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are rare, life-threatening diseases in which chronically elevated pressure in the pulmonary arteries results in vascular remodeling and right heart failure. Treatment goals are to improve patient functioning, exercise capacity, and symptoms; delay disease progression; normalize the right...
متن کاملWhat is new about Rio?
This issue of the European Respiratory Journal includes the results of three different studies of riociguat, a soluble guanylate cyclase stimulator, for the treatment of pulmonary hypertension [1–3]. As the first drug in a novel class for the treatment of pulmonary hypertension, riociguat has raised hopes of an expanded drug armamentarium against the still incurable diseases of pulmonary arteri...
متن کاملRiociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
Clinical background Despite recent advances, the prognosis for patients with pulmonary hypertension remains poor. Riociguat (BAY 63-2521) is a novel oral stimulator of the nitric oxide (NO) receptor soluble guanylate cyclase, and synergizes with low levels of bioavailable NO. Its safety and efficacy in dose titration were studied in patients with PAH (n = 33) or CTEPH (n = 42) in this multicent...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- P & T : a peer-reviewed journal for formulary management
دوره 39 11 شماره
صفحات -
تاریخ انتشار 2014